Recently stock market analysts have updated their consensus ratings on shares of bluebird bio, Inc. (NASDAQ:BLUE). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/05/2016 – bluebird bio, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 80 price target on the stock.

05/05/2016 – bluebird bio, Inc. had its “buy” rating reiterated by analysts at BTIG Research. They now have a USD 72 price target on the stock.

04/21/2016 – bluebird bio, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 149 price target on the stock.

04/20/2016 – bluebird bio, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 105 price target on the stock.

04/05/2016 – bluebird bio, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 67 price target on the stock.

03/18/2016 – bluebird bio, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 117 price target on the stock.

02/18/2016 – bluebird bio, Inc. had its “neutral” rating reiterated by analysts at Roth Capital. They now have a USD 62 price target on the stock.

01/05/2016 – Janney Montgomery Scott began new coverage on bluebird bio, Inc. giving the company a “buy” rating. They now have a USD 91 price target on the stock.

12/07/2015 – bluebird bio, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 117 price target on the stock.

12/07/2015 – bluebird bio, Inc. was downgraded to “neutral” by analysts at Bank of America Merrill Lynch. They now have a USD 102 price target on the stock.

12/07/2015 – bluebird bio, Inc. was downgraded to “equal-weight” by analysts at Morgan Stanley. They now have a USD 69 price target on the stock.

12/03/2015 – Wells Fargo began new coverage on bluebird bio, Inc. giving the company a “outperform” rating.

11/16/2015 – bluebird bio, Inc. had its “outperform” rating reiterated by analysts at Cowen.

11/05/2015 – bluebird bio, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 162 price target on the stock.

10/20/2015 – bluebird bio, Inc. had its “overweight” rating reiterated by analysts at JP Morgan.

bluebird bio, Inc. has a 50 day moving average of 45.34 and a 200 day moving average of 57.15. The stock’s market capitalization is 1.42B, it has a 52-week low of 36.94 and a 52-week high of 197.35.

The share price of the company (NASDAQ:BLUE) was down -0.47% during the last trading session, with a high of 39.22 and the volume of bluebird bio, Inc. shares traded was 904573.

View other investors thoughts on bluebird bio, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.